The Decision Support System ("DSS") of glucome customizes treatment recommendations, guaranteeing an optimal oral drug intensification (second and third line) for patients with type 2 diabetes mellitus type 2
The Digital Diabetes Management provider, GlucoMe [ Link announced today that its new System System (DSS "decision) has the CE certification.The DSS is a support for reliable clinical decisions and based on algorithms that helps doctors to ensure an oral drug intensification for patients with type 2 diabetes mellitus (T2DM).
Diabetes is a progressive disorder and despite the guidelines that order a drug intensification within 3 to 6 months from the initial treatment, it is often delayed.This can lead to insufficient diabetes control and is associated with health complications.Glucome DSS uses an advanced patented algorithm that allows real -time analysis of specific data with treatment recommendations.The algorithm complies 100% of internationally recognized medication guidelines (Consensus of Ada and EASD guidelines, 2018).The glucome solution helps to cover the void in maintaining drug intensification deadlines, allowing doctors to customize T2DM management and improve treatment.
The cloud -based solution /SAAS of Gluccome obtained similar medication recommendations in pilot studies to endocrinologists and overcame those of head doctors, primary medical care providers.The algorithm generated medical recommendations that were 98% according to endocrinologists against 82% according to general medicine doctors.
"Receiving CE certification is a great leap forward to complete our vision of offering a complete digital platform that allows the efficient and complete treatment of diabetes," said Glucome CEO, Yiftah Ben-Aharon."Health care providers and doctors can now have a valuable and practical tool that allows decision making to customize Patient treatment plans T2DM. Use DSS will allow better diabetes control by ensuring that each patient receives treatmenttimely, in addition to reducing the costs associated with the complications of diabetes. "
The DSS Glucome can be integrated into a Software EHR - EMR of third parties or operate directly from the digital platform Diabetes Management of Glucome.
About glucome
GlucoMe [ Link is a digital health company that innovates and markets a complete digital solution for the treatment of diabetes.
With the new System System Decision based on algorithms that analyzes data on diabetes and offers medical equipment treatment recommendations, Glukome is in the process of making its vision come true to offer an autonomous health care platform for diabetes.
The glucome solution allows intelligent care and control contained, rationalizing and simplifying the care of diabetes for patients, caregivers and medical professionals.The platform integrates a management of each patient and a population, designed to efficiently increase involvement and compliance.Its central architecture allows the rapid and simple implementation and allows organizations to easily climb while offering quality treatment.
The Glukome platform includes an affordable wireless blood glucose monitor that operates with patented audio connectivity;a mobile application compatible with iOS and Android devices;A digital diabetes Clinic - a cloud -based diabetes control management software for organizations andhealth professionals;and a control tower, which allows the prioritization and management of populations and patient data.
